Precision Medicine Products
Cellworks provides two products for Oncologists to assist in treating patients previously diagnosed with specific oncology indications. Cellworks translates the molecular and genomic knowledge of the patient’s tumor into actionable interventions, after analyzing the effectiveness of FDA-approved drugs on the patient’s tumor.
SINGULATM SoC Response
SingulaTM predicts whether a targeted standard-of-care (SoC) targeted drug therapy will produce response in the patient. By predictively separating responders from non-responders, the physician has an actionable decision making ability for optimized therapy. This can save vital time for the patient as well as control treatment costs.
Say you, the physician, are presented with a MDS patient who has TET1, TET2, MTHFR, MTRR, TP53, APC, AXIN2 and ASXL1 mutations and a complex cytogenetics profile with loss of various chromosomal segments. SingulaTM can help guide you whether the patient with this set of genomic aberrations is likely to respond a MDS standard-of-care drug like Azacitidine or Lenalidomide.
SingulaTM can be considered for treatment-naïve patients.
VENTURATM Ideal Combination
After the standard-of-care therapies are exhausted, or after the patient has relapsed, the current protocol is to send the patient to clinical trials or to palliative care. Cellworks offers another option. VenturaTM informs you, the physician, of the likely ideal combination of all FDA-approved drugs to produce the response in the patient. In determining this optimal combination, on-label oncology drugs, off-label oncology drugs and non-oncology drugs are all investigated before a recommendation is made.
Say you, the physician, are presented with an AML patient who has HER2, FGFR4, IL4R, IL6R, IL7, TET1, DNMT3L mutations, and various other genes have copy number variations and are amplified (ACLY, NRG1, FGFR1, FGFR3, LYN) or deleted (TET3). VenturaTM will help guide you as to which combination of FDA-approved drugs this AML patient is likely to respond to.
VenturaTM can be considered for refractory or relapsed patients.
Personalized Cancer Therapy
Cellworks starts once an NGS report has been produced. A key barrier to adoption of NGS reports has been the lack of clinical utility. Once a physician orders an NGS report, the report often provides un-actionable information. While previously evaluating a patient’s disease status with difficult options for treatment decisions, the NGS report now adds an additional level of complexity without necessarily providing anymore clarity or guidance towards the ultimate decision regarding treatment. Cellworks increases clinical utility and adoption of NGS by understanding the clinician’s needs.
Precision Medicine Workflow
Based on the genomic profile of the patient, Cellworks provides patient-specific reports for improved efficacy. Each report includes full transparent patient-specific causal rationale for each therapy suggested. The turnaround time for a Cellworks report is typically 72 hours once an NGS report is produced.